BA
ADPT icon

Bridgewater Associates’s Adaptive Biotechnologies ADPT Stock Holding History

Bridgewater Associates’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$860K Sell
40,087
-49,620
-55% -$760K ﹤0.01% 857
2026
Q1 		$1.25M Sell
89,707
-175,784
-66% -$2.8M 0.01% 752
2025
Q4 		$4.31M Buy
265,491
+114,237
+76% +$1.86M 0.02% 577
2025
Q3 		$2.26M Buy
+151,254
New +$1.84M 0.01% 703

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Bridgewater Associates's ADPT Position: Q2 2026 in Review

Bridgewater Associates reduced its Adaptive Biotechnologies (ADPT) stake by 55% in Q2 2026, selling an estimated $760K and leaving 40,087 shares worth $860K. The position accounts for ﹤0.01% of the portfolio, ranked #857.

Bridgewater Associates first reported a position in ADPT in Q3 2025 and has held it in 4 quarters since. The position peaked at $4.31M in Q4 2025. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Bridgewater Associates held 40,087 shares of Adaptive Biotechnologies worth $860K as of Q2 2026.
  • Bridgewater Associates sold 49,620 Adaptive Biotechnologies shares in Q2 2026, an estimated $760K.
  • Adaptive Biotechnologies made up ﹤0.01% of Bridgewater Associates's portfolio in Q2 2026, its #857 holding.
  • Bridgewater Associates first reported a position in Adaptive Biotechnologies in Q3 2025 and has held it in 4 quarters since.
  • Bridgewater Associates's Adaptive Biotechnologies position peaked at $4.31M in Q4 2025.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Bridgewater Associates's 13F filing for Q2 2026, filed 14 Aug 2026.